top of page

Reproductive & Endocrine Systems

Glucagon, somatostatin, and pancreatic polypeptide

Core Principle of Pancreatic Islet Counter-Regulatory Hormones
🧷 The endocrine pancreas contains four major cell types: β cells (insulin), α cells (glucagon), δ cells (somatostatin), and PP cells (pancreatic polypeptide).
🧷 While insulin promotes anabolism and glucose storage, glucagon opposes insulin by promoting catabolism and glucose release — maintaining glucose homeostasis through reciprocal regulation.
🧷 Somatostatin acts as the universal brake, inhibiting secretion of both insulin and glucagon, while pancreatic polypeptide modulates digestive processes.
🧷 Understanding these hormones requires thinking in terms of metabolic states: fed versus fasted, and how the body coordinates fuel mobilization.
Solid White Background
Glucagon Structure and Synthesis
📍 Glucagon is a 29-amino acid peptide hormone synthesized in pancreatic α cells from proglucagon.
📍 The proglucagon gene yields tissue-specific products: glucagon in α cells, but GLP-1 and GLP-2 in intestinal L cells — explaining why GLP-1 agonists don't cause hypoglycemia.
📍 Glucagon has a very short half-life (~5 minutes), allowing rapid on-off switching of its catabolic effects.
📍 Board pearl: Glucagon and GLP-1 come from the same precursor but have opposite effects on glucose — glucagon raises it, GLP-1 lowers it by enhancing insulin secretion.
Solid White Background
Glucagon Secretion Triggers and Inhibitors
🔹 Primary stimuli: hypoglycemia (most potent), amino acids (especially arginine and alanine), sympathetic activation (β-adrenergic), cortisol.
🔹 Primary inhibitors: hyperglycemia, insulin, somatostatin, GLP-1, fatty acids.
🔹 The postprandial amino acid rise explains why protein meals stimulate both insulin AND glucagon — preventing hypoglycemia from protein-induced insulin secretion.
🔹 During prolonged fasting, falling insulin removes tonic suppression of α cells, allowing glucagon to rise and maintain euglycemia.
🔹 Board clue: Mixed meal → both insulin and glucagon rise; pure glucose load → insulin rises, glucagon falls.
Solid White Background
Glucagon Mechanism of Action
⭐ Glucagon binds Gs-coupled receptors primarily in liver (also kidney, heart, adipose tissue) → ↑cAMP → PKA activation.
⭐ In liver: PKA phosphorylates key enzymes, activating catabolic pathways and inhibiting anabolic ones.
⭐ The cAMP-PKA cascade amplifies the signal — one glucagon molecule can generate thousands of glucose molecules.
⭐ Glucagon effects are rapid (minutes) for glycogenolysis but slower (hours) for gluconeogenesis due to required enzyme induction.
⭐ Board pearl: Glucagon works through the same cAMP-PKA pathway as epinephrine in liver, but glucagon is more potent and specific for hepatic glucose production.
Solid White Background
Glucagon's Hepatic Effects: The Catabolic Cascade
✅ Glycogenolysis: PKA phosphorylates phosphorylase kinase → activates glycogen phosphorylase → glucose release within 5-10 minutes.
✅ Gluconeogenesis: induces PEPCK, fructose-1,6-bisphosphatase, glucose-6-phosphatase → glucose synthesis from lactate, amino acids, glycerol.
✅ Fatty acid oxidation: ↓acetyl-CoA carboxylase → ↓malonyl-CoA → disinhibition of CPT1 → fatty acids enter mitochondria for β-oxidation.
✅ Ketogenesis: acetyl-CoA from β-oxidation → HMG-CoA → ketone bodies (acetoacetate, β-hydroxybutyrate).
✅ Board distinction: Insulin promotes energy storage; glucagon promotes energy mobilization and oxidation.
Solid White Background
Glucagon in Lipid and Protein Metabolism
🧠 Adipose tissue: promotes lipolysis → free fatty acids and glycerol released → substrate for hepatic gluconeogenesis and ketogenesis.
🧠 Protein metabolism: increases hepatic amino acid uptake and transamination → carbon skeletons for gluconeogenesis, nitrogen for urea cycle.
🧠 The combination of proteolysis and ureagenesis explains the negative nitrogen balance seen in uncontrolled diabetes or prolonged fasting.
🧠 Glucagon does NOT directly affect muscle protein breakdown — that's mediated by cortisol and lack of insulin.
🧠 Board pearl: Glucagon mobilizes all three macronutrients, but its primary board-tested effects are on glucose and ketone production.
Solid White Background
Somatostatin: The Universal Inhibitor
⚡ Somatostatin is a 14 or 28 amino acid peptide (two active forms) produced by pancreatic δ cells, hypothalamus, GI tract D cells.
⚡ Acts through Gi-coupled receptors → ↓cAMP → inhibits hormone secretion and reduces GI motility and secretion.
⚡ Pancreatic effects: inhibits insulin, glucagon, and pancreatic polypeptide — preventing excessive swings in glucose.
⚡ GI effects: inhibits gastrin, CCK, secretin, motilin, VIP, GIP → reduced acid secretion, enzyme secretion, and gut motility.
⚡ Board pearl: Somatostatin inhibits virtually everything — think of it as the body's brake pedal for both endocrine and exocrine secretion.
Solid White Background
Somatostatin Regulation and Clinical Correlates
📌 Stimulated by: hyperglycemia, amino acids, fatty acids, CCK, glucagon — essentially all nutrients and gut hormones.
📌 Inhibited by: α-adrenergic stimulation, low glucose.
📌 Paracrine action is key — δ cells are strategically positioned to sense and modulate neighboring α and β cell secretion.
📌 Octreotide (somatostatin analog) clinical uses: acromegaly, carcinoid syndrome, VIPomas, variceal bleeding, persistent hypoglycemia from insulinoma.
📌 Board clue: Patient with secretory diarrhea from VIPoma or carcinoid → octreotide reduces hormone secretion and improves symptoms.
Solid White Background
Pancreatic Polypeptide: The Satiety Signal
📣 PP is a 36-amino acid peptide from pancreatic PP cells (also called F cells), primarily in the pancreatic head.
📣 Secretion is under vagal control — rises with meals (especially protein), peaks at 10-20 minutes, remains elevated for 4-6 hours.
📣 Acts centrally to reduce appetite and food intake; peripherally to slow gastric emptying and reduce pancreatic enzyme secretion.
📣 PP levels are used clinically to assess vagal integrity and distinguish type 3c (pancreatogenic) from type 1/2 diabetes.
📣 Board pearl: PP is the only pancreatic hormone that requires intact vagal innervation for normal meal-stimulated secretion.
Solid White Background
Integration of Islet Cell Paracrine Signaling
🔸 Islet architecture enables paracrine regulation: β cells in core, α and δ cells in mantle → insulin inhibits glucagon; somatostatin inhibits both.
🔸 Blood flows from β-cell core to α/δ-cell periphery, allowing insulin to suppress glucagon secretion directly.
🔸 Gap junctions between β cells synchronize insulin pulses; similar connections coordinate α cell responses.
🔸 Loss of paracrine regulation in diabetes: β cell destruction → loss of tonic glucagon suppression → inappropriate hyperglucagonemia → worsened hyperglycemia.
🔸 Board concept: Type 1 diabetes involves both insulin deficiency AND glucagon excess due to lost paracrine inhibition.
Solid White Background
Glucagon in Hypoglycemia Defense
🧷 First defense (glucose ~80 mg/dL): ↓insulin secretion.
🧷 Second defense (glucose ~65-70 mg/dL): ↑glucagon and ↑epinephrine.
🧷 Third defense (glucose ~55-60 mg/dL): ↑cortisol and growth hormone.
🧷 Glucagon provides rapid glucose recovery via hepatic glycogenolysis; epinephrine provides backup when glucagon is deficient.
🧷 Board pearl: In type 1 diabetes with frequent hypoglycemia → impaired glucagon response (α cell dysfunction) → increased reliance on epinephrine → if autonomic neuropathy present → hypoglycemia unawareness and severe risk.
Solid White Background
Clinical Glucagonoma Syndrome
📍 Rare α cell tumor secreting excessive glucagon → characteristic syndrome.
📍 Necrolytic migratory erythema: pathognomonic rash with erythematous patches, central clearing, bronze induration — affects intertriginous areas.
📍 Glucose intolerance/diabetes: from unopposed glucagon action.
📍 Weight loss, anemia, glossitis, cheilitis: from increased protein catabolism and amino acid depletion.
📍 Venous thrombosis risk increased.
📍 Board clue: Diabetic patient + characteristic migratory rash + weight loss → measure glucagon levels → if >1000 pg/mL → glucagonoma.
Solid White Background
Somatostatinoma: The Inhibitory Syndrome
🔹 Rare δ cell tumor causing excessive somatostatin → inhibition of multiple hormones.
🔹 Triad: diabetes (inhibited insulin), cholelithiasis (inhibited CCK → gallbladder stasis), steatorrhea (inhibited pancreatic enzymes).
🔹 Often associated with neurofibromatosis type 1.
🔹 May present with dyspepsia, hypochlorhydria (inhibited gastrin), weight loss.
🔹 Diagnosis: elevated somatostatin levels + imaging showing pancreatic or duodenal mass.
🔹 Board distinction: Glucagonoma → too much stimulation; somatostatinoma → too much inhibition.
Solid White Background
Therapeutic Uses of Glucagon
⭐ Severe hypoglycemia: 1 mg IM/SC → raises glucose within 10-15 minutes by hepatic glycogenolysis (ineffective if glycogen depleted).
⭐ Beta-blocker overdose: bypasses β-receptor blockade via direct cAMP activation in heart → positive inotropic/chronotropic effects.
⭐ Esophageal food bolus: smooth muscle relaxation (off-label use).
⭐ Diagnostic imaging: GI hypomotility for better visualization.
⭐ Board pearl: Glucagon won't work for hypoglycemia in alcohol intoxication or prolonged starvation — these states deplete hepatic glycogen stores.
Solid White Background
Fasting Physiology and Hormonal Coordination
✅ Early fasting (0-4 hours): insulin falls, glucagon rises modestly → hepatic glucose output matches peripheral utilization.
✅ Prolonged fasting (>24 hours): glucagon remains elevated → glycogen exhausted → gluconeogenesis becomes primary glucose source.
✅ Starvation (>72 hours): glucagon drives ketogenesis → brain shifts to ketone utilization → glucose sparing for obligate users (RBCs, renal medulla).
✅ Counter-regulatory failure in diabetes: cannot suppress glucagon → excessive hepatic glucose output even when glucose is already elevated.
✅ Board concept: Fasting = ↓insulin/glucagon ratio; feeding = ↑insulin/glucagon ratio.
Solid White Background
Islet Cell Tumors and MEN Syndromes
🧠 Insulinoma: most common islet tumor → hypoglycemia with ↑insulin, ↑C-peptide, ↑proinsulin.
🧠 Gastrinoma: second most common → Zollinger-Ellison syndrome (peptic ulcers, diarrhea, GERD).
🧠 VIPoma: watery diarrhea, hypokalemia, achlorhydria (WDHA syndrome).
🧠 Glucagonoma and somatostatinoma: rare but characteristic syndromes.
🧠 Board association: Multiple islet tumors + hyperparathyroidism + pituitary adenoma → MEN1; islet tumor + pheochromocytoma + medullary thyroid cancer → consider MEN2.
Solid White Background
Laboratory Testing and Hormone Measurement
⚡ Glucagon normal range: 50-150 pg/mL; >1000 pg/mL suggests glucagonoma.
⚡ Somatostatin: not routinely measured due to short half-life; somatostatin-like immunoreactivity used instead.
⚡ Pancreatic polypeptide: elevated in islet tumors (non-specific marker), low in chronic pancreatitis and vagal dysfunction.
⚡ Dynamic testing: glucagon stimulation test evaluates pituitary and adrenal reserve; arginine stimulation assesses α cell function.
⚡ Board tip: Random hormone levels less useful than stimulation/suppression tests for functional assessment.
Solid White Background
Integration with Incretin System
📌 GLP-1 and GIP are incretins — gut hormones that augment insulin secretion in response to oral nutrients.
📌 GLP-1 also suppresses glucagon, but only when glucose is elevated → why GLP-1 agonists rarely cause hypoglycemia.
📌 Somatostatin inhibits both GLP-1 and GIP secretion from intestinal cells.
📌 In type 2 diabetes: impaired incretin effect contributes to postprandial hyperglycemia and inappropriate glucagon secretion.
📌 Board connection: DPP-4 inhibitors prevent incretin breakdown → enhanced insulin, suppressed glucagon → improved glucose without hypoglycemia risk.
Solid White Background
Board Question Stem Patterns
📣 Diabetic + migratory rash + weight loss → glucagonoma until proven otherwise.
📣 Diabetes + gallstones + steatorrhea → somatostatinoma.
📣 Hypoglycemic patient given glucagon with no response → consider alcohol intoxication or glycogen storage disease.
📣 Type 1 diabetic with recurrent severe hypoglycemia → impaired glucagon and epinephrine responses.
📣 Octreotide for GI bleeding → reduces splanchnic blood flow via inhibition of vasodilatory hormones.
📣 Post-gastrectomy patient with better glucose control → loss of incretin-stimulated insulin and glucagon.
📣 MEN1 patient with peptic ulcers → gastrinoma most likely, but screen for other islet tumors.
Solid White Background
One-Line Recap
🔸 Glucagon (α cells) opposes insulin by promoting hepatic glucose output and ketogenesis via cAMP-PKA signaling, while somatostatin (δ cells) inhibits both insulin and glucagon to prevent metabolic extremes, and pancreatic polypeptide (PP cells) modulates satiety and digestive functions — together maintaining glucose homeostasis through intricate paracrine networks disrupted in diabetes and rare islet cell tumors.
Solid White Background
bottom of page